Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of Xalkori ROS1
Sponsor: Pfizer
Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Official title: XALKORI ROS1+NSCLC DRUG USE INVESTIGATION
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
97
Start Date
2017-10-25
Completion Date
2026-11-06
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
crizotinib
XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows. " The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
Locations (1)
Pfizer
Tokyo, Japan